SORRENTO THERAPEUTICS, INC., based in San Diego, California, is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases and bringing effective, non-opioid, pain medications to the market.  SORRENTO’s approach to fighting cancer is made possible by its unique immune-oncology (“I-O”) portfolio, comprised of a wide array of innovative and synergistic assets such as a broad fully human antibody library (“G-MAB™”), clinical stage chimeric antigen receptor-T cells (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”), and an oncolytic virus (“Sephrehvir®”). The Company has generated fully human antibodies against many targets including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, and CCR2, which are at various stages of development.  It’s CAR-T programs include clinical stage CEA CAR-T and preclinical stage CD38 CAR-T.  Cross-portfolio asset combination therapies are in preclinical stage evaluation for multiple myeloma, metastatic liver cancer, and other adult and pediatric cancers.

SORRENTO’s non-opioid pain management portfolio includes:  ZTlido, a next generation lidocaine patch launched in October 2018; SP-102, a gel aimed at lumbar radicular pain and sciatica, currently in Phase 3; and RTX, a potent compound with many potential uses currently in a Phase 1B trial against osteoarthritis pain.